Early Release - COVID-19 in Patient with Sarcoidosis Receiving Long-Term #Hydroxychloroquine Treatment, France, 2020 - Volume 26, Number 10—October 2020 - Emerging Infectious Diseases journal - CDC
▻https://wwwnc.cdc.gov/eid/article/26/10/20-1816_article
Un cas de personne qui a développé une #COVID-19 malgré la prise régulière (et efficace) d’HCQ (et seulement d’HCQ) pour une maladie chronique (Sarcoidose).
Des publications antérieures allaient dans le même sens (pas d’effet préventif de l’#HCQ) mais celle-ci est la seule où le patient ne prenait QUE de l’HCQ (des immunosuppresseurs y étaient associés dans les précédentes).
This observation of COVID-19 with diffuse interstitial pneumonia requiring hospital admission in a patient on long-term hydroxychloroquine treatment suggests that hydroxychloroquine may not be as effective as suggested by in vitro data. This patient had always been considered highly adherent to his medications, which was confirmed by therapeutic drug monitoring. Because plasma concentration was within therapeutic range by the time the patient was admitted, the failure of hydroxychloroquine to prevent COVID-19 cannot be attributed to underdosage or suboptimal adherence. Two recent studies suggested that hydroxychloroquine provides no protection against COVID-19 in patients with a broad range of autoimmune diseases from New York, USA (3), and in patients with systemic lupus erythematosus from France (4). The case we present is unique in that the patient was not receiving any immunomodulatory agent other than hydroxychloroquine.
